

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-100559-PIP01-22)
MHRA-100559-PIP01-22-M01

Scope of the Application

Active Substance(s)

MITAPIVAT SULFATE

Condition(s)

Treatment of thalassaemia

Pharmaceutical Form(s)

Film-coated tablet Age-appropriate oral solid dosage form (coated granules)

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

Agios Netherlands B.V.

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Agios Netherlands B.V. submitted to the licensing authority on 11/03/2026 14:15 GMT an application for a Modification

The procedure started on 30/03/2026 09:16 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to link this PIP with related PIP Decision (MHRA-100608-PIP01-22-M01) covering indications for mitapivat for treatment of pyruvate kinase deficiency (PK deficiency) including all subsequent modifications thereof.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100559-PIP01-22-M01

Of 06/07/2026 14:19 BST

On the adopted decision for MITAPIVAT SULFATE (MHRA-100559-PIP01-22-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for MITAPIVAT SULFATE, Film-coated tablet Age-appropriate oral solid dosage form (coated granules) , ORAL USE .

This decision is addressed to Agios Netherlands B.V., Zuidplein 36, Regus Amsterdam WTC, Amsterdam, NETHERLANDS, 1077XV

ANNEX I

1. Waiver

1.1 Condition:

Treatment of thalassaemia The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 1 year of age Pharmaceutical form(s): Film-coated tablet Age-appropriate oral solid dosage form (coated granules) Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of thalassaemia

2.2 Indication(s) targeted by the PIP:

Treatment of paediatric patients with thalassaemia

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 1 year to less than 18 years of age

2.4 Pharmaceutical Form(s):

Film-coated tablet Age-appropriate oral solid dosage form (coated granules)

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 (Same as Study 1 of MHRA-100608-PIP01-22-M01 and subsequent modifications thereof) Development of an age-appropriate oral solid dosage form (coated granules) for use in paediatric patients unable to swallow the available tablets.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	2	Study 2 Double-blind, randomised, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of mitapivat in children from 1 year to less than 18 years of age with alpha- or beta-transfusion-dependent thalassemia. Study 3 Double-blind, randomised, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of mitapivat in children from 1 year to less than 18 years of age with alpha- or beta- non-transfusion-dependent thalassemia.
Extrapolation, Modeling & Simulation Studies	0	Not applicable.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	30/06/2029
Deferral of one or more studies contained in the paediatric investigation plan:	Yes